Here’s Who Just Picked Up Otonomy Inc. (NASDAQ:OTIC) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Otonomy Inc. (NASDAQ:OTIC) reported that Federated Investors Inc /pa/. has picked up 2,937,800 of common stock as of 2017-02-14.
The acquisition brings the aggregate amount owned by Federated Investors Inc /pa/. to a total of 2,937,800 representing a 9.74% stake in the company.
For those not familiar with the company, Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration. Its product candidates include OTIPRIO, OTO-104 and OTO-311. The Company’s product candidate, OTIPRIO, is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery. Its product candidate, OTO-104, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere’s disease and other inner ear conditions. The Company’s product candidate, OTO-311, is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus.
A glance at Otonomy Inc. (NASDAQ:OTIC)’s key stats reveals a current market capitalization of 460.46 million based on 30.19 million shares outstanding and a price at last close of $15.20 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-05-22, Capps picked up 1,600 at a purchase price of $24.35. This brings their total holding to 1,600 as of the date of the filing.
On the sell side, the most recent transaction saw Butt unload 1,456 shares at a sale price of $18.07. This brings their total holding to 9,458.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Otonomy Inc. (NASDAQ:OTIC) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Federated Investors Inc. Picked Up Contrafect Corp. (NASDAQ:CFRX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Contrafect Corp (NASDAQ:CFRX) reported that Federated Investors Inc /pa/ has picked up 4,000,000 of common stock as of 2017-02-14.
The acquisition brings the aggregate amount owned by Federated Investors Inc /pa/ to a total of 4,000,000 representing a 9.18% stake in the company.
For those not familiar with the company, Contrafect Corp (NASDAQ:CFRX) is a biotechnology company focused on developing treatments for drug resistant, life-threatening infectious diseases. Their lysin and monoclonal antibody products represent new approaches to treating infections.
A glance at Contrafect Corp. (NASDAQ:CFRX)’s key stats reveals a current market capitalization of 70.68 million based on 41.58 million shares outstanding and a price at last close of $1.71 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-07-27, Keizer picked up 20,000 at a purchase price of $2.48. This brings their total holding to 20,000 as of the date of the filing.
On the sell side, the most recent transaction saw Couto unload 2,872 shares at a sale price of $3.81. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Contrafect Corp. (NASDAQ:CFRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Vaccinogen Inc. (OTCMKTS:VGEN) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Vaccinogen Inc. (OTCMKTS:VGEN) reported that Mpm Bioventures Iii L.p. has picked up 134,452 of common stock as of 2017-02-13.
The acquisition brings the aggregate amount owned by Mpm Bioventures Iii L.p. to a total of 134,452 representing a 0.4% stake in the company.
For those not familiar with the company, Vaccinogen, Inc. is a biotechnology company. The Company is the developer of OncoVAX. OncoVAX is an active specific immunotherapy (ASI) that uses the patient’s own cancer cells to create a vaccine that in turn is used to block the return of cancer following surgery. OncoVAX is a patient specific immunotherapy for stage II colon cancer and its technology may have application in other tumor types, such as melanoma and renal cell carcinoma. The OncoVAX patient-specific vaccine consists of sterile, metabolically active, irradiated and non-tumorigenic autologous cancer cells, with or without fresh frozen Bacillus Calmette-Guerin (BCG) bacteria as an adjuvant. The Company has completed a Phase IIIa study of OncoVAX.
A glance at Vaccinogen Inc. (OTCMKTS:VGEN)’s key stats reveals a current market capitalization of 7.24 million based on 37.32 million shares outstanding and a price at last close of 0.169 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2014-12-26, Halldin picked up 934,580 at a purchase price of $5.50. This brings their total holding to 934,580 as of the date of the filing.
On the sell side, the most recent transaction saw Hanna unload 1,000 shares at a sale price of $3.61. This brings their total holding to 224,587.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Vaccinogen Inc (OTCMKTS:VGEN) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Primecap Management Co/ca/ Picked Up Accuray Inc. (NASDAQ:ARAY) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Accuray Inc. (NASDAQ:ARAY) reported that Primecap Management Co/ca/ has picked up 5,513,300 of common stock as of 2017-02-13.
The acquisition brings the aggregate amount owned by Primecap Management Co/ca/ to a total of 5,513,300 representing a 6.75% stake in the company.
For those not familiar with the company, Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.
A glance at Accuray Inc. (NASDAQ:ARAY)’s key stats reveals a current market capitalization of 455.94 million based on 82.90 million shares outstanding and a price at last close of $5.50 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-11-9, Levine picked up 50,000 at a purchase price of $7.12. This brings their total holding to 1,115,830 as of the date of the filing.
On the sell side, the most recent transaction saw Nouri unload 957 shares at a sale price of $6.80. This brings their total holding to 65,547.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Accuray Inc. (NASDAQ:ARAY) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
OrbiMed Advisors is Buying Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) reported that OrbiMed Advisors has picked up 2,524,000 of common stock as of 2017-02-13.
The acquisition brings the aggregate amount owned by OrbiMed Advisors to a total of 2,524,000 representing a 1.73% stake in the company.
For those not familiar with the company, Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. It operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. It is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD). Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD. It has two sGC development candidates, which include IW-1973 and IW-1701.
A glance at Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD)’s key stats reveals a current market capitalization of 2.41 billion based on 130.86 million shares outstanding and a price at last close of $16.42 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2011-11-02, Hecht picked up 50,000 at a purchase price of $11.65. This brings their total holding to 72,803 as of the date of the filing.
On the sell side, the most recent transaction saw Hecht unload 32,994 shares at a sale price of $15.50. This brings their total holding to 4,670,322.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Up Integra Lifesciences Holdings Corp. (NASDAQ:IART) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Integra Lifesciences Holdings Corp. (NASDAQ:IART) reported that Caruso Richard E. has picked up 6,201,027 of common stock as of 2017-02-13.
The acquisition brings the aggregate amount owned by Caruso Richard E. to a total of 6,201,027 representing a 16.57% stake in the company.
For those not familiar with the company, Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties. Its product category includes products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care, including product portfolios used in neurosurgery operation suites and critical care units, and Orthopedics and Tissue Technologies, which offers products of a combination of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities.
A glance at Integra Lifesciences Holdings Corp (NASDAQ:IART)’s key stats reveals a current market capitalization of 3.20 billion based on 74.77 million shares outstanding and a price at last close of $42.90 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2011-11-02, Caruso picked up 2,000 at a purchase price of $28.46. This brings their total holding to 2,000 as of the date of the filing.
On the sell side, the most recent transaction saw Arduini unload 20,000 shares at a sale price of $80.02. This brings their total holding to 25,593.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Integra Lifesciences Holdings Corp. (NASDAQ:IART) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Heron Therapeutics Inc. (NASDAQ:HRTX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Heron Therapeutics Inc. (NASDAQ:HRTX) reported that Broadfin Capital has picked up 3,916,534 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Broadfin Capital to a total of 3,916,534 representing a 9.99% stake in the company.
For those not familiar with the company, Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company’s SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
A glance at Heron Therapeutics Inc. (NASDAQ:HRTX)’s key stats reveals a current market capitalization of 718.68 million based on 51.47 million shares outstanding and a price at last close of $13.55 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-19, Poyhonen picked up 10,000 at a purchase price of $12.20. This brings their total holding to 10,000 as of the date of the filing.
On the sell side, the most recent transaction saw Rosen unload 12,400 shares at a sale price of $23.89. This brings their total holding to 2,640.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Heron Therapeutics Inc. (NASDAQ:HRTX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Vanguard Group Inc. Picked Up Cognizant Technology Solutions Corp. (NASDAQ:CTSH) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Cognizant Technology Solutions Corp. (NASDAQ:CTSH) reported that Vanguard Group Inc. has picked up 39,165,838 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Vanguard Group Inc. to a total of 39,165,838 representing a 6.45% stake in the company.
For those not familiar with the company, Cognizant Technology Solutions Corporation is a provider of information technology (IT), consulting and business process services. The Company operates through four segments: Financial Services, which includes customers providing banking/transaction processing, capital markets and insurance services; Healthcare, which includes healthcare providers and payers, as well as life sciences customers, including pharmaceutical, biotech and medical device companies; Manufacturing, Retail and Logistics, which includes manufacturers, retailers, travel and other hospitality customers, as well as customers providing logistics services, and Other, which includes communications, manufacturing/retail/logistics, and high technology. The Company’s competencies include business, process, operations and IT consulting, application development and systems integration, enterprise information management, application testing, application maintenance and IT infrastructure services.
A glance at Cognizant Technology Solutions Corp. (NASDAQ:CTSH)’s key stats reveals a current market capitalization of 35.96 billion based on 606.60 million shares outstanding and a price at last close of $57.68 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2014-12-16, Patsalos-Fox picked up 10,000 at a purchase price of $51.70. This brings their total holding to 11,028 as of the date of the filing.
On the sell side, the most recent transaction saw Kandiah unload 20,000 shares at a sale price of $55.53. This brings their total holding to 12,072.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Cognizant Technology Solutions Corp. (NASDAQ:CTSH) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.